TNFSF13
Tumor necrosis factor ligand superfamily member 13
As of the edition of 20 October 2026, TNFSF13 (tumor necrosis factor ligand superfamily member 13, UniProt O75888) has 2 drugs tested at it and 4 companies on the list, 0 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- O75888
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- Secreted
- Solved structures
- 1
- Disease areas
- Immune system; Pregnancy and women's health; Urinary and reproductive; Skin and connective tissue; Bones, joints and muscles; Eye; Mouth and teeth; Nervous system
- Registered trials of its drugs
- 25
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Atacicept | Marketed | Phase 3 | Ends 2038 |
| Sibeprenlimab | Marketed | Phase 3 | Ends 2037 |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 2 |
| Engaged | 1 |
| Undetermined | 1 |
| Total on the list | 4 |
| Company | Route |
|---|---|
| Otsuka | Route B |
| Vera Therapeutics | Route B |
The other 2 companies at TNFSF13
In the product4 companies in all; 2 are not named here, and no score is.
See the 4 companies at TNFSF13, ranked, with the facts behind eachRequest access. Nothing is shown until you do.